Besides, trastuzumab-deruxtecan (T-Dxd) with a cleavable linkage to a potent topoisomerase I inhibitor payload and excellent membrane permeability, which laid the foundation for the treatment of HER2-low breast cancer (28). Here, ERBB2 is linked to breast carcinoma.